IDSA updates guidance for antimicrobial-resistant gram-negative infections

• by Meg Barbor

• August 21, 2026

The rationale for ophthalmic vigilance during the 2026 Hantavirus outbreak

• by Aaron T. Zhao, Jordan D. Deaner

• September 9, 2026

Can LAI-CAB Sustain Long-Term PrEP Use?

A national claims analysis found modest uptake and declining persistence over 2 years despite increasing use of injectable HIV pre-exposure prophylaxis.

• by Andrea Surnit

• July 17, 2026

• 4 min

FDA approves pritelivir for refractory HSV lesions

In a phase 3 trial, complete lesion healing occurred in 63% of patients receiving pritelivir vs. 34% receiving comparator treatments.

• by Teraya Smith

• October 9, 2026

• 2 min